![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
The agreement aims to develop a drug discovery platform that targets Tumor Macrophage Hybrid (TMH) cells to eliminate the most resilient cancers and stop disease recurrence.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Columbia University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 17, 2023